Table 3. Multivariable analysis of cohorts 1 and 2.
| Cohort 1: Capecitabine | Cohort 2: 5-FU | |||||||
|---|---|---|---|---|---|---|---|---|
| ypCR | ypCR + ypPR | ypCR | ypCR + ypPR | |||||
| OR (95%CI) |
p value | OR (95%CI) |
p value | OR (95%CI) |
p value | OR (95%CI) |
p value | |
| Age (≥ 65 years) | 0.51 (0.22–1.17) | 0.11 | - | - | - | - | - | - |
| Sex (male) | - | - | 1.39 (0.70–2.79) | 0.35 | - | - | 2.22 (1.05–4.85) | 0.046 |
| Comorbidities (yes) | - | - | 1.60 (0.78–3.29) | 0.20 | - | - | 2.62 (1.01–6.79) | 0.047 |
| Clinical stage (III) | 0.76 (0.29–2.03) | 0.59 | 0.49 (0.22–1.09) | 0.08 | 1.30 (0.55–3.07) | 0.54 | 0.50 (0.22–1.05) | 0.09 |
| PPI (no) | 1.10 (0.42–2.91) | 0.85 | - | - | - | - | 2.08 (0.83–5.20) | 0.12 |
| Radiotherapy (3D) | - | - | 0.39 (0.18–0.83) | 0.01 | 0.32 (0.07–1.51) | 0.15 | - | - |
| Time RT – Surgery (> 8 weeks) |
- | - | 0.52 (0.25–1.10) | 0.08 | - | - | - | - |
| RT duration (>5 weeks) | 2.60 (1.06–6.38) | 0.04 | - | - | - | - | - | - |
| Clinical response (yes)a | 21.67 (8.92–52.68) | <0.001 | 4.09 (1.91–8.74) | <0.001 | 15.21 (2.21–12.31) | <0.001 | - | - |
a
Clinical complete response was used for ypCR analysis and clinical complete + partial response for ypCR + ypPR analysis
OR: odds ratio; 95% CI: 95% CI; y: years; PPI: proton-pump inhibitors; RT: radiotherapy
The bold values represent statistical significant factors associated with ypCR and ypCR+ypPR in multivariable analysis in both cohorts 1 and 2